ELYM Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 4.70%

Insider Buying (Last 12 Months): $49,952,816.64

Insider Selling (Last 12 Months): $2,136,493.93

Eliem Therapeutics Insider Trading History Chart

Eliem Therapeutics Share Price & Price History

^$7.98

▲ +0.02 (0.25%)

As of 09/18/2024 01:00 AM ET

Days: 30 | 90 | 365

Kamala Harris and The Woke Progressive Nightmare

From Paradigm Press | Ad

New research from Jim Rickards - former advisor to the CIA - reveals shocking predictions about an “Election Meltdown” coming this November.

Click here now to see Jim’s shocking predictions for November.

Eliem Therapeutics Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
7/22/2024	Valerie Morisset	EVP	Sell	69,005	$8.03	$554,110.15	31,317
7/19/2024	Valerie Morisset	EVP	Sell	60,201	$7.21	$434,049.21	100,322
7/17/2024	Valerie Morisset	EVP	Sell	3,207	$6.91	$22,160.37	199,099
7/15/2024	Valerie Morisset	EVP	Sell	42,377	$7.01	$297,062.77	252,306
7/11/2024	Valerie Morisset	EVP	Sell	50,000	$7.11	$355,500.00	344,683
7/9/2024	Valerie Morisset	EVP	Sell	5,931	$6.66	$39,500.46	444,683
7/5/2024	Valerie Morisset	EVP	Sell	12,342	$7.06	$87,134.52	450,614
7/3/2024	Valerie Morisset	EVP	Sell	50,000	$6.76	$338,000.00	462,956
6/27/2024	Ra Capital Management, L.P.	Director	Buy	13,008,546	$3.84	$49,952,816.64	23,521,757
6/20/2024	Emily Pimblett	CAO	Sell	1,245	$7.21	$8,976.45	3,755

Kamala Harris and The Woke Progressive Nightmare

From Paradigm Press | Ad

New research from Jim Rickards - former advisor to the CIA - reveals shocking predictions about an “Election Meltdown” coming this November.

Click here now to see Jim’s shocking predictions for November.

SEC Filings (Institutional Ownership Changes) for Eliem Therapeutics (NASDAQ:ELYM)

69.76% of Eliem Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Eliem Therapeutics Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
8/16/2024	Driehaus Capital Management LLC	696,057	$4.95M	0.0%	-14.2%	2.340%
8/15/2024	Affinity Asset Advisors LLC	1,670,661	$11.88M	1.4%	N/A	5.615%
8/14/2024	Ally Bridge Group NY LLC	500,000	$3.56M	2.1%	N/A	1.681%
8/9/2024	Renaissance Technologies LLC	37,000	$0.26M	0.0%	+248.5%	0.124%
8/9/2024	Dimensional Fund Advisors LP	12,560	$89K	0.0%	N/A	0.042%
8/1/2024	Rhumbline Advisers	8,233	$59K	0.0%	N/A	0.028%
7/26/2024	Bank of New York Mellon Corp	18,845	$0.13M	0.0%	N/A	0.063%
4/23/2024	BML Capital Management LLC	2,193,742	$6.01M	4.0%	+0.6%	7.914%
1/30/2024	BML Capital Management LLC	2,180,000	$5.89M	4.4%	+12.5%	7.907%
1/26/2024	Cerity Partners LLC	13,821	$37K	0.0%	N/A	0.050%
11/13/2023	Silverarc Capital Management LLC	121,110	$0.32M	0.1%	-75.5%	0.447%
10/23/2023	BML Capital Management LLC	1,938,263	$5.10M	4.7%	+22.4%	7.155%
8/15/2023	Silverarc Capital Management LLC	494,089	$1.38M	0.4%	+1.7%	1.830%
8/14/2023	Driehaus Capital Management LLC	810,593	$2.27M	0.0%	+20.3%	3.003%
7/24/2023	BML Capital Management LLC	1,583,170	$4.43M	4.0%	-4.5%	5.866%
4/14/2023	BML Capital Management LLC	1,658,170	$4.81M	4.2%	-9.1%	6.148%
2/14/2023	Driehaus Capital Management LLC	551,942	$2.03M	0.0%	+58.3%	2.077%
2/13/2023	BML Capital Management LLC	1,825,134	$6.70M	6.4%	N/A	6.869%
2/1/2023	Bank of Montreal Can	25,244	$93K	0.0%	N/A	0.095%
11/8/2022	Atom Investors LP	67,074	$0.22M	0.1%	+154.9%	0.252%
10/28/2022	Silverarc Capital Management LLC	402,088	$1.30M	0.4%	-43.6%	1.513%
8/16/2022	Parkwood LLC	67,202	$67K	0.2%	+63.4%	0.253%
7/25/2022	Silverarc Capital Management LLC	713,009	$2.15M	0.7%	+707.7%	2.684%
5/12/2022	Monashee Investment Management LLC	227,201	$1.91M	0.6%	-24.3%	0.855%
5/9/2022	Qube Research & Technologies Ltd	15,874	$0.13M	0.0%	N/A	0.060%
2/19/2022	Woodline Partners LP	373,368	$3.91M	0.1%	-3.6%	1.406%
2/15/2022	Samlyn Capital LLC	1,703,546	$17.82M	0.2%	+1.3%	6.417%
2/11/2022	Parkwood LLC	30,609	$0.32M	0.1%	N/A	0.115%
2/7/2022	Monashee Investment Management LLC	300,000	$3.14M	0.8%	-1.7%	1.130%
2/2/2022	New York State Common Retirement Fund	3,359	$35K	0.0%	N/A	0.013%
1/28/2022	Allspring Global Investments Holdings LLC	2,880	$30K	0.0%	N/A	0.011%
12/29/2021	Hudson Bay Capital Management LP	100,000	$1.80M	0.0%	N/A	0.377%
11/15/2021	Tudor Investment Corp Et Al	287,294	$5.17M	0.0%	N/A	1.082%
11/15/2021	RA Capital Management L.P.	13,150,849	$236.45M	3.3%	N/A	49.536%
11/15/2021	Caas Capital Management LP	75,000	$1.35M	0.0%	N/A	0.283%
11/12/2021	Geode Capital Management LLC	76,904	$1.38M	0.0%	N/A	0.290%
11/10/2021	Goldman Sachs Group Inc.	165,952	$2.98M	0.0%	N/A	0.625%
11/9/2021	BlackRock Inc.	332,126	$5.97M	0.0%	N/A	1.251%
11/9/2021	Monashee Investment Management LLC	305,233	$5.49M	1.0%	N/A	1.150%
11/4/2021	Deutsche Bank AG	4,063	$73K	0.0%	N/A	0.015%

Data available starting January 2016

Eliem Therapeutics, Inc., a biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. The company was incorporated in 2018 and is headquartered in Wilmington, Delaware.

Today's Range

Now: $7.98

$7.81

$8.14

50 Day Range

MA: $7.19

$5.81

$8.93

52 Week Range

Now: $7.98

$2.35

$11.55

Volume

413,419 shs

Average Volume

415,040 shs

Market Capitalization

$237.42 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of Eliem Therapeutics?: Eliem Therapeutics' top insider shareholders include:
Ra Capital Management, LP (Director)
Valerie Morisset (EVP)
Emily Pimblett (CAO)
Learn More about top insider investors at Eliem Therapeutics.
Who are the major institutional investors of Eliem Therapeutics?: Eliem Therapeutics' top institutional shareholders include:
Affinity Asset Advisors LLC — 5.62%
Driehaus Capital Management LLC — 2.34%
Ally Bridge Group NY LLC — 1.68%
Renaissance Technologies LLC — 0.12%
Bank of New York Mellon Corp — 0.06%
Dimensional Fund Advisors LP — 0.04%
Learn More about top institutional investors of Eliem Therapeutics stock.
Which institutional investors are selling Eliem Therapeutics stock?: During the last quarter, ELYM stock was sold by these institutional investors:
Driehaus Capital Management LLC
In the last year, company insiders that have sold Eliem Therapeutics company stock include:
Ra Capital Management, LP (Director)
Valerie Morisset (EVP)
Learn More investors selling Eliem Therapeutics stock.
Which institutional investors are buying Eliem Therapeutics stock?: In the last quarter, ELYM stock was purchased by institutional investors including:
Affinity Asset Advisors LLC
Ally Bridge Group NY LLC
Renaissance Technologies LLC
Bank of New York Mellon Corp
Dimensional Fund Advisors LP
Rhumbline Advisers